Physiotherapeutic Approach to Superficial and Deep Dyspareunia in Women With Chronic Pelvic Pain: Comparison Between In-person and Telehealth Care.

June 16, 2026 updated by: Hellen Maria Feitoza De Almeida, University of Sao Paulo
Adequate sexual function is considered an important factor in satisfaction and overall quality of life for both men and women. It is estimated 16% to 40% of women suffer from some form of sexual dysfunction, which is currently considered a public health problem and its investigation is recommended because it causes significant changes in the quality of life of these women. Among the painful disorders, genitopelvic pain, which includes dyspareunia, vaginismus and vulvodynia, dyspareunia stands out, which involves the appearance of pain during or after sexual intercourse, directly affecting physical health, as well as sexual and mental well-being. Among the treatment techniques for dyspareunia in women with chronic pelvic pain, there is the Thiele massage, which provides an inhibitory effect on muscle tension caused by spasms, relaxing, stretching and relieving coital pain. In this sense, we know that physiotherapy treatment has an important role in improving pain symptoms, since musculoskeletal dysfunction may be present in women with dyspareunia, which makes it relevant to verify whether the approach via telecare would have the same effectiveness as the in-person technique that has scientific proof, since through telecare the woman would not be exposed to the risks that are inherent to going to an outpatient clinic, it could cover more women and this would also bring a greater cost-benefit to the unified health system.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • São Paulo
      • Ribeirão Preto, São Paulo, Brazil, 14048-900
        • Ribeirão Preto Clinical Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Women diagnosed with CPP and deep or shallow penetration dyspareunia;
  • Over 18 years of age;
  • Willingness to voluntarily participate in the study, accepting randomization to either of the two treatment arms;
  • Signature of the Free and Informed Consent Form (FICF).

Exclusion Criteria:

  • Women with penetrative dyspareunia without pelvic floor muscle spasm;
  • Women without an active sex life

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Face-to-face treatment
Treatment through face-to-face outpatient care
Procedure: Face-to-face treatment
Massage in the direction of the muscle fibers with a pressure tolerable for the patient for 5 minutes. The treatment will be carried out in the outpatient clinic by a previously trained physiotherapist.
Active Comparator: Telecare
Teleservice via video call
Procedure: Telecare
Massage in the direction of the muscle fibers with a pressure tolerable for the patient for 5 minutes. The treatment will be carried out by the patient at home and guided by a previously trained physiotherapist via teleconsultation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual Analog Scale (EAV)
Time Frame: From acceptance to participate in the study until the end in 10 weeks in the reassessment.
The visual analog scale (VAS) for pain is the most widely used unidimensional scale in clinical practice due to its feasibility, speed, and clinical application. It measures pain from 0 to 10, with higher scores indicating greater pain.
From acceptance to participate in the study until the end in 10 weeks in the reassessment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Sao Paulo

Collaborators

University of Sao Paulo General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 16, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

January 1, 2028

Study Registration Dates

First Submitted

May 23, 2026

First Submitted That Met QC Criteria

June 16, 2026

First Posted (Actual)

June 22, 2026

Study Record Updates

Last Update Posted (Actual)

June 22, 2026

Last Update Submitted That Met QC Criteria

June 16, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 7.460.314

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All IPR collected, all IPR that underpins the results of a publication.

IPD Sharing Time Frame

July 2025-January 2028

IPD Sharing Access Criteria

Researchers who conduct studies on chronic pelvic pain

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surface and Deep Dyspareunia

Clinical Trials on Face-to-face treatment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe